Effective January 1, 2026, Rosemont Pharmaceuticals has announced the appointment of Alok Sonig as its new Chief Executive Officer, marking a significant leadership transition for the organization.
Alok Soni brings close to 30 years of experience in the global pharmaceutical industry, with leadership roles spanning strategy, research and development, biosimilars, and commercial operations across multiple geographies.
Prior to joining Rosemont Pharmaceuticals, he was with Baxter International Inc., where he most recently served as Executive Vice President and Group President, Pharmaceuticals, overseeing the company’s pharmaceutical business globally.
Before his tenure at Baxter, Alok held several senior leadership positions at leading pharmaceutical organizations. He served as CEO of Lupin Pharmaceuticals (US Pharmaceuticals), as Global Head of R&D and Biosimilars, and later as CEO – Developed Markets at Dr. Reddy’s Laboratories, with responsibility for markets including the United States, Canada, Europe, and Japan.
Earlier in his career, Alok spent nearly 15 years at Bristol Myers Squibb, where he held multiple executive roles across general management, global strategy, and marketing, contributing to the company’s growth in highly competitive and regulated markets.
The appointment reflects Rosemont Pharmaceuticals’ focus on seasoned leadership with deep global exposure, particularly at a time when pharmaceutical organizations are navigating evolving regulatory landscapes, innovation pressures, and market expansion strategies.
At MedicinMan, we track leadership movements across the healthcare ecosystem that signal strategic shifts and long-term industry direction.
